HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
CANTON, Mass., April 04, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
